Supernus Pharmaceuticals, Inc.
A maker of brain and nervous-system medicines, Supernus develops and sells branded treatments for ADHD, Parkinson's disease, epilepsy, and postpartum depression—brands like Qelbree, GOCOVRI, Trokendi XR, and ZURZUVAE. It began in 2005 as a spin-out of Shire Laboratories, founded by Jack Khattar, who then bought the very business he had led. Its name comes from Latin for "from above," a fitting label for a company born out of the lab it once ran.
Granted 1.82M · Sold 985.3K
Granted 73.0K · Sold 44.2K
Granted 30.4K · Sold 31.2K
Granted 12.0K
Granted 73.0K · Sold 30.6K
Granted 79.7K · Sold 57.7K
Granted 21.8K
Granted 84.0K · Sold 61.5K
Granted 275.8K · Sold 254.9K
Granted 18.9K · Sold 927
Granted 33.4K · Sold 11.8K
Granted 7.5K · Sold 8.9K
Granted 9.8K · Sold 9.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Khattar Jack A.President, CEO, Director · 119 transactions | +39.6% | 4.40M | 1.82M | — | 985.3K |
| Newhall Charles W IIIDirector · 16 transactions | +27.3% | 124.1K | 73.0K | — | 44.2K |
| Martin Tami TillotsonSr. V.P., Regulatory Affairs · 16 transactions | -2.8% | 86.9Kas of Feb 2024 | 30.4K | — | 31.2K |
| Siebert John MDirector · 3 transactions | +10.7% | 84.1Kas of Feb 2024 | 12.0K | — | — |
| Hudson Frederick M.Director · 14 transactions | +234.9% | 60.4K | 73.0K | — | 30.6K |
| Gemayel GeorgesDirector · 16 transactions | +592.1% | 36.1K | 79.7K | — | 57.7K |
| Barlow CarroleeDirector · 5 transactions | +419% | 27.0K | 21.8K | — | — |
| Mottola FrankSVP, Chief Tech. Ops. Officer · 48 transactions | +169.6% | 18.4K | 84.0K | — | 61.5K |
| Bhatt Padmanabh P.Sr. VP of IP, CSO · 76 transactions | — | 17.5K | 275.8K | — | 254.9K |
| Rubin JonathanSVP, Chief Medical Officer · 30 transactions | — | 13.3K | 18.9K | — | 927 |
| Dec Timothy CSenior Vice-President & CFO · 34 transactions | — | 8.1K | 33.4K | — | 11.8K |
| Horich William ToddSVP, Commercial Operations · 8 transactions | — | 4.8K | 7.5K | — | 8.9K |
| Sensenig BethanyDirector · 5 transactions | — | 4.5K | 9.8K | — | 9.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.50M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.